Study that looked at the effect of different doses of PF-05221304 on the amount of fat in the liver

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate Safety, Tolerability, and Pharmacodynamics of PF-05221304 Administered Daily for 16-Weeks to Adult Subjects With Nonalcoholic Fatty Liver Disease

Category & Conditions:
Diabetes and Metabolic Disorders
PF-05221304 Identifier (NCT):
Protocol ID:
Open Plain Language Summary Result:Click here